Form 4 for RNXT RenovoRx, Inc.

Accepted 2026-03-24 00:00:00 ET · period of report 2026-03-20 · accession 0001493152-26-012482 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
DI	2026-03-24	2026-03-20	RNXT	Bagai Shaun	CEO, Dir	P - Purchase	—	+24.3K	313.4K	+8%	—
DI	2026-03-24	2026-03-20	RNXT	Bagai Shaun	CEO, Dir	P - Purchase	—	+12.2K	12.2K	New	—

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2026-03-20	P	A	24,300	—	313,357	I The Bagai Family Trust	—	—	(F1) The securities were purchased in a private placement on March 20, 2026 for an aggregate of $25,000. (F3) 289,057 shares of common stock are held of record by The Bagai Family Trust and were previously reported as "directly" beneficially held by the Reporting Person.
2	Derivative	Warrants	2026-03-20	P	A	12,150	—	12,150	I The Bagai Family Trust	$1.93 · — to —	12,150 Common Stock	(F1) The securities were purchased in a private placement on March 20, 2026 for an aggregate of $25,000. (F2) The warrants are exercisable immediately upon issuance and expire on the earlier of (i) March 30, 2029 or (ii) 30 days following the date the Issuer reports at least $1.5 million in product sales revenue (excluding licensing fees, upfront milestones and grants, but including royalty revenue from product sales) for any calendar quarter in a quarterly or annual report.